日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

FDA批准摘要:呋喹替尼用于治疗难治性转移性结直肠癌

Fusco, Michael J; Casak, Sandra J; Mushti, Sirisha L; Cheng, Joyce; Christmas, Brian J; Thompson, Matthew D; Fu, Wentao; Wang, Hezhen; Yoon, Miyoung; Yang, Yuching; Moore, Jason N; Bi, Youwei; Nan, Yang; Long, Craig E; Auth, Doris; Rahman, Nam A; Tang, Shenghui; Pazdur, Richard; Fashoyin-Aje, Lola A; Kluetz, Paul G; Lemery, Steven J

FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor

FDA批准摘要:瑞普替尼用于治疗晚期胃肠道间质瘤

Kumar, Vaibhav; Doros, Leslie; Thompson, Margaret; Mushti, Sirisha L; Charlab, Rosane; Spehalski, Elizabeth I; Zhao, Hong; Thompson, Matthew D; Tang, Shenghui; Pazdur, Richard; Lemery, Steven J; Theoret, Marc R; Fashoyin-Aje, Lola A

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

FDA批准摘要:Futibatinib用于治疗不可切除的晚期或转移性、化疗难治性肝内胆管癌,伴有FGFR2融合或其他重排

Gandhy, Shruti U; Casak, Sandra J; Mushti, Sirisha L; Cheng, Joyce; Subramaniam, Sriram; Zhao, Hong; Zhao, Miao; Bi, Youwei; Liu, Guansheng; Fan, Jianghong; Adeniyi, Oluseyi; Charlab, Rosane; Kufrin, Dubravka; Thompson, Matthew D; Jarrell, Kristin; Auth, Doris; Lemery, Steven J; Pazdur, Richard; Kluetz, Paul G; Fashoyin-Aje, Lola A

Monitoring response to a clinically relevant IDH inhibitor in glioma-Hyperpolarized (13)C magnetic resonance spectroscopy approaches

利用超极化(13)C磁共振波谱法监测胶质瘤对临床相关IDH抑制剂的反应

Hong, Donghyun; Kim, Yaewon; Mushti, Chandrasekhar; Minami, Noriaki; Wu, Jing; Cherukuri, Murali Krishna; Swenson, Rolf E; Vigneron, Daniel B; Ronen, Sabrina M

General Method to Increase Carboxylic Acid Content on Nanodiamonds

提高纳米金刚石上羧酸含量的一般方法

Shenoy, Ganesh; Ettedgui, Jessica; Mushti, Chandrasekhar; Hong, Jennifer; Lane, Kelly; Blackman, Burchelle; Jung, Hak-Sung; Takagi, Yasuharu; Seol, Yeonee; Brechbiel, Martin; Swenson, Rolf E; Neuman, Keir C

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

FDA批准摘要:帕博利珠单抗用于一线治疗MSI-H/dMMR晚期不可切除或转移性结直肠癌患者

Casak, Sandra J; Marcus, Leigh; Fashoyin-Aje, Lola; Mushti, Sirisha L; Cheng, Joyce; Shen, Yuan-Li; Pierce, William F; Her, Leah; Goldberg, Kirsten B; Theoret, Marc R; Kluetz, Paul G; Pazdur, Richard; Lemery, Steven J

Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy

纳武利尤单抗治疗既往接受过氟尿嘧啶和铂类化疗的不可切除的晚期、复发性或转移性食管鳞状细胞癌患者的获益风险总结

Pelosof, Lorraine; Saung, May Tun; Donoghue, Martha; Casak, Sandra; Mushti, Sirisha; Cheng, Joyce; Jiang, Xiling; Liu, Jiang; Zhao, Hong; Khazraee, Maryam; Goldberg, Kirsten B; Theoret, Marc; Lemery, Steven; Pazdur, Richard; Fashoyin-Aje, Lola

Simple Esterification of [1-(13)C]-Alpha-Ketoglutarate Enhances Membrane Permeability and Allows for Noninvasive Tracing of Glutamate and Glutamine Production

[1-(13)C]-α-酮戊二酸酯的简单酯化可增强膜通透性,并允许对谷氨酸和谷氨酰胺的生成进行无创追踪。

AbuSalim, Jenna E; Yamamoto, Kazutoshi; Miura, Natsuko; Blackman, Burchelle; Brender, Jeffrey R; Mushti, Chandrasekhar; Seki, Tomohiro; Camphausen, Kevin A; Swenson, Rolf E; Krishna, Murali C; Kesarwala, Aparna H

Synthesis of [1-(13) C-5-(12) C]-alpha-ketoglutarate enables noninvasive detection of 2-hydroxyglutarate

[1-(13)C-5-(12)C]-α-酮戊二酸的合成实现了2-羟基戊二酸的非侵入性检测

Miura, Natsuko; Mushti, Chandrasekhar; Sail, Deepak; AbuSalim, Jenna E; Yamamoto, Kazutoshi; Brender, Jeffrey R; Seki, Tomohiro; AbuSalim, Deyaa I; Matsumoto, Shingo; Camphausen, Kevin A; Krishna, Murali C; Swenson, Rolf E; Kesarwala, Aparna H

Photoinducible Oncometabolite Detection

光诱导癌代谢物检测

Kulkarni, Rhushikesh A; Briney, Chloe A; Crooks, Daniel R; Bergholtz, Sarah E; Mushti, Chandrasekhar; Lockett, Stephen J; Lane, Andrew N; Fan, Teresa W-M; Swenson, Rolf E; Marston Linehan, W; Meier, Jordan L